Last Update 12 May 26

ABT: Medtech Pipeline And Dividend Record Will Support Future Repricing

Analysts have trimmed Abbott Laboratories' consolidated price target by $1, reflecting a slightly higher discount rate, a marginally lower revenue growth outlook, a very small adjustment to profit margin assumptions, and a modestly lower future P/E multiple in light of several recent target cuts and a removal from a conviction list.

Analyst Commentary

Recent Street research on Abbott Laboratories has tilted more cautious, with a series of price target reductions and a removal from a major conviction list. Even so, the research still highlights some supportive elements for the story alongside the concerns around valuation and execution.

Bullish Takeaways

Bullish analysts who previously raised targets point to what they see as generally healthy sector fundamentals in medical technology, which can support Abbott's longer term positioning if the company executes consistently.
Some research notes maintain positive stock ratings even as price targets are adjusted, indicating that certain analysts still view the shares as having upside potential relative to where they see fair value.
The breadth of coverage and ongoing target fine tuning suggest analysts are closely engaged with Abbott's portfolio and end markets, which can help investors benchmark expectations on growth and profitability against peers.

Bearish Takeaways

Bearish analysts have cut price targets by a wide range, from low single digit to much larger dollar amounts, which reflects reduced conviction on how much investors should pay for Abbott's earnings profile.
The removal of Abbott from a prominent US conviction list signals that at least one high profile research team now sees a less compelling risk reward trade off for the stock compared with other opportunities.
Several firms have trimmed organic growth outlooks and become more cautious on execution, indicating that expectations for revenue and margin delivery are being reset lower in their valuation work.
Downgrades and repeatedly lower targets cluster over a short time frame, which can reinforce a more guarded stance among institutional investors that rely on Street research when assessing position size and entry levels.

What's in the News

A jury awarded US$70 million in damages in an Illinois trial related to Similac Special Care and necrotizing enterocolitis in four pre-term infants, with Abbott held liable for defective design, failure to warn, and negligence (Bloomberg / Keller Postman verdict).
Abbott received U.S. Food and Drug Administration clearance for its Ultreon 3.0 Software, an AI enabled optical coherence tomography platform intended to support more precise stent sizing and placement in complex coronary procedures.
New late breaking clinical data across multiple trials highlighted outcomes for Abbott's pulsed field ablation and conduction system pacing portfolios, including FlexPulse IDE, ASCEND CSP IDE and LEAP2 early feasibility studies for atrial fibrillation and heart rhythm disorders.
Abbott presented additional data on its Cancerguard multi cancer early detection blood test program at the American Association for Cancer Research Annual Meeting 2026, including biomarker performance findings and recognition for DETECT A multi year outcomes research.
Abbott and Flatiron Health announced that Abbott's Precision Oncology testing portfolio is now integrated into Flatiron's OncoEMR platform, allowing oncology providers to order tests and receive results directly in their existing electronic medical record workflow.

Valuation Changes

Fair Value: $118.64 is unchanged in the updated model, indicating no adjustment to the consolidated fair value estimate.
Discount Rate: risen slightly from 8.01% to 8.02%, reflecting a marginally higher required return on equity cash flows.
Revenue Growth: trimmed slightly from 9.75% to 9.75%, a very small downward adjustment to the long term growth assumption.
Net Profit Margin: inched up from 15.93% to 15.93%, reflecting a very small improvement in projected profitability.
Future P/E: reduced moderately from 27.80x to 27.48x, pointing to a lower valuation multiple applied to future earnings in the updated framework.

5 views

Key Takeaways

Strong demand from emerging markets and aging populations, along with new product launches, is expected to fuel sustained growth and diversify revenue streams.
Innovation in high-margin medical technologies and a diversified business mix will drive market share gains and support stable, long-term earnings.
Margin and revenue growth are threatened by pricing pressures, regulatory risks, intensifying competition, global volatility, and increased investment requirements across Abbott's core business segments.

Catalysts

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.What are the underlying business or industry changes driving this perspective?

The expansion of healthcare access and rising middle class in key emerging markets (such as India, China, Latin America, and the Middle East) is fueling robust growth in branded generics and biosimilars, highlighted by Abbott's record sales in these regions and imminent biosimilar launches; this trend is poised to drive sustained double-digit top-line growth and greater geographic revenue diversification.
The global demographic shift toward an aging population and increasing prevalence of chronic and lifestyle-related diseases (e.g., diabetes, cardiovascular disease) is underpinning strong, recurring demand for Abbott's diagnostics, nutrition (e.g., Ensure, Glucerna), and high-growth medical device franchises-supporting revenue acceleration and enhanced operating leverage.
Abbott's ongoing innovation in high-margin segments, most notably through the FreeStyle Libre franchise (with next-gen, dual-analyte sensors and new software integrations) and pipeline launches in structural heart and rhythm management devices, positions the company to capture incremental market share and drive net margin expansion.
Recent headwinds (COVID testing declines, China diagnostics procurement, and HIV funding) are transient and expected to lapse by 2026, while new product launches (biosimilars, next-gen devices, systems integration) and regulatory expansions are set to accelerate revenue growth and improve earnings visibility.
Abbott's ability to leverage existing infrastructure and cross-segment synergies in emerging markets, coupled with a diversified business mix across nutrition, diagnostics, devices, and established pharmaceuticals, reduces earnings volatility and should support stable long-term earnings and margin improvement.

Abbott Laboratories Earnings and Revenue Growth

Abbott Laboratories Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Abbott Laboratories's revenue will grow by 9.7% annually over the next 3 years.
Analysts assume that profit margins will increase from 13.9% today to 15.9% in 3 years time.
Analysts expect earnings to reach $9.5 billion (and earnings per share of $5.45) by about May 2029, up from $6.3 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $11.1 billion in earnings, and the most bearish expecting $7.1 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 27.5x on those 2029 earnings, up from 23.0x today. This future PE is greater than the current PE for the GB Medical Equipment industry at 24.1x.
Analysts expect the number of shares outstanding to grow by 0.11% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.02%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Diagnostic sales are experiencing significant headwinds due to declining COVID testing demand, ongoing effects from volume-based procurement (VBP) in China, and reduced US foreign aid funding for HIV testing; if VBP-related price erosion or Chinese market volatility persists or worsens, it could create persistent downward pressure on Diagnostic division revenues and overall company top-line growth.
The company faces exposure to tariffs (expected ~$200 million impact) and adverse foreign exchange movements (ongoing EPS headwind of up to 4%), both of which could compress operating margins and earnings, particularly if trade tensions or global currency volatility intensifies.
Competitive bidding initiatives for continuous glucose monitors (CGM) in the US, coupled with rising competition from other CGM providers and potential commoditization of diagnostic and device platforms, threaten Abbott's pricing power and could erode net margins and long-term revenue growth in its core diabetes franchise.
While international expansion, especially in emerging markets and branded generics, is currently driving growth, overdependence on these geographies exposes Abbott to risks from changing regulatory policies, government price controls, and currency fluctuations, potentially making future earnings less predictable.
Ongoing litigation risk (e.g., infant formula MDL), regulatory hurdles (including potential for stricter or lengthier device and biosimilar approval processes), and the need for significant R&D and SG&A investment to support new product development and launches may raise costs, delay time-to-market, and impact overall profitability and net margins over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $118.64 for Abbott Laboratories based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $143.0, and the most bearish reporting a price target of just $92.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $59.7 billion, earnings will come to $9.5 billion, and it would be trading on a PE ratio of 27.5x, assuming you use a discount rate of 8.0%.
Given the current share price of $82.56, the analyst price target of $118.64 is 30.4% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Abbott Laboratories?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead